Corrigendum to "Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist" [Mol. Cell. Endocrinol. 283 (2008) 49-57] (DOI:10.1016/j.mce.2007.11.020);Liquiritigenin is a plant-derived highly selective estrogen receptor β agonist

Molecular and Cellular Endocrinology

Volumn 283, Issue 1-2, 2008, Pages 49-57

  Mersereau, Jennifer E ^a   Levy, Nitzan ^a   Staub, Richard E ^b   Baggett, Scott ^b   Zogric, Tetjana ^a   Chow, Sylvia ^b   Ricke, William A ^c   Tagliaferri, Mary ^b   Cohen, Isaac ^b   Bjeldanes, Leonard F ^d   Leitman, Dale C ^a,d  

^a Cellular and Molecular Pharmacology   (United States)

^b Bionovo   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Estrogen receptor beta; Estrogen response element; Gene regulation; Herbs; MCF 7 cells; Phytoestrogens

Indexed keywords

ANDROGEN RECEPTOR; LIQUIRITIGENIN; PROGESTERONE;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; DRUG ACTIVITY; DRUG STRUCTURE; GENE ACTIVATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 39149111920     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.09.001     Document Type: Erratum

References (42)

1. An J., Ribeiro R.C., Webb P., Gustafsson J.A., Kushner P.J., Baxter J.D., and Leitman D.C. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15161-15166
2. An J., Tzagarakis-Foster C., Scharschmidt T.C., Lomri N., and Leitman D.C. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276 (2001) 17808-17814
3. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L., Wactawski-Wende J., Wallace R., and Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
4. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., and Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 (1998) 105-112
5. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A., Khandekar J., Petrovitch H., and McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
6. Cranney A., and Adachi J.D. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 28 (2005) 721-730
7. Cvoro A., Tzagarakis-Foster C., Tatomer D., Paruthiyil S., Fox M.S., and Leitman D.C. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol. Cell 21 (2006) 555-564
8. Cvoro A., Paruthiyil S., Jones J.O., Tzagarakis-Foster C., Clegg N.J., Tatomer D., Medina R.T., Tagliaferri M., Schaufele F., Scanlan T.S., Diamond M.I., Cohen I., and Leitman D.C. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 148 (2007) 538-547
9. Delmas P., Bjarnason N., Mitlak B., Ravoux A.-C., Shah A., Huster W., Draper M., and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
10. Evans M.L., Pritts E., Vittinghoff E., McClish K., Morgan K.S., and Jaffe R.B. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet. Gynecol. 105 (2005) 161-166
11. Fu B., Li H., Wang X., Lee F.S., and Cui S. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J. Agric. Food Chem. 53 (2005) 7408-7414
12. Harris H.A., Albert L.M., Leathurby Y., Malamas M.S., Mewshaw R.E., Miller C.P., Kharode Y.P., Marzolf J., Komm B.S., Winneker R.C., Frail D.E., Henderson R.A., Zhu Y., and Keith Jr. J.C. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144 (2003) 4241-4249
13. Hewitt S.C., Harrell J.C., and Korach K.S. Lessons in estrogen biology from knockout and transgenic animals. Annu. Rev. Physiol. 67 (2005) 285-308
14. Kian Tee M., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., Yamamoto K.R., and Leitman D.C. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors {alpha} and {beta}. Mol. Biol. Cell 15 (2004) 1262-1272
15. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., and Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998) 4252-4263
16. Levy N., Zhao X., Tang H., Jaffe R.B., Speed T.P., and Leitman D.C. Multiple transcription factor elements collaborate with ER{alpha} to activate an inducible estrogen response element in the NKG2E gene. Endocrinology 148 (2007) 3449-3558
17. Levy, N., Tatomer, D., Herber, C.B., Zhao, X., Tang, H., Sargeant, T., Ball, L.J., Summers, J., Speed, T.P., Leitman, D.C., 2008. Differential regulation of Native Estrogen Receptor Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene. Mol. Endocrinol., in press.
18. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L., Novotny P.J., Dakhil S.R., Rodger K., Rummans T.A., and Christensen B.J. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356 (2000) 2059-2063
19. Loprinzi L., Barton D.L., Sloan J.A., Zahasky K.M., Smith de A.R., Pruthi S., Novotny P.J., Perez E.A., and Christensen B.J. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin. Proc. 77 (2002) 1159-1163
20. Love R., Mazess R., Barden H., Epstein S., Newcomb P., Jordan V., Carbone P., and DeMets D. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856
21. Maggiolini M., Statti G., Vivacqua A., Gabriele S., Rago V., Loizzo M., Menichini F., and Amdo S. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 82 (2002) 315-322
22. Malamas M.S., Manas E.S., McDevitt R.E., Gunawan I., Xu Z.B., Collini M.D., Miller C.P., Dinh T., Henderson R.A., Keith Jr. J.C., and Harris H.A. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J. Med. Chem. 47 (2004) 5021-5040
23. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., and Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349 (2003) 523-534
24. Nelson H.D., Vesco K.K., Haney E., Fu R., Nedrow A., Miller J., Nicolaidis C., Walker M., and Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295 (2006) 2057-2071
25. Oerter Klein K., Janfaza M., Wong J.A., and Chang R.J. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J. Clin. Endocrinol. Metab. 88 (2003) 4077-4079
26. Parmar H., Young P., Emerman J.T., Neve R.M., Dairkee S., and Cunha G.R. A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology 143 (2002) 4886-4896
27. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., and Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64 (2004) 423-428
28. Petri Nahas E., Nahas Neto J., De Luca L., Traiman P., Pontes A., and Dalben I. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 48 (2004) 372-380
29. Ricke W.A., Ishii K., Ricke E.A., Simko J., Wang Y., Hayward S.W., and Cunha G.R. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer 118 (2006) 2123-2131
30. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
31. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., Ko M., LaCroix A.Z., Margolis K.L., and Stefanick M.L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
32. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones III B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., and Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
33. Shumaker S.A., Legault C., Kuller L., Rapp S.R., Thal L., Lane D.S., Fillit H., Stefanick M.L., Hendrix S.L., Lewis C.E., Masaki K., and Coker L.H. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 (2004) 2947-2958
34. Sicat B.L., and Brokaw D.K. Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy 24 (2004) 79-93
35. Somjen D., and Yoles I. DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J. Steroid Biochem. Mol. Biol. 86 (2003) 93-98
36. Somjen D., Katzburg S., Knoll E., Hendel D., Stern N., Kaye A.M., and Yoles I. DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM). J. Steroid Biochem. Mol. Biol. 104 (2007) 252-258
37. Strom A., Hartman J., Foster J.S., Kietz S., Wimalasena J., and Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1566-1571
38. Uesugi S., Watanabe S., Ishiwata N., Uehara M., and Ouchi K. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Biofactors 22 (2004) 221-228
39. Upchurch D.M., Chyu L., Greendale G.A., Utts J., Bair Y.A., Zhang G., and Gold E.B. Complementary and alternative medicine use among American women: findings from The National Health Interview Survey 2002. J. Womens Health (Larchmt) 16 (2007) 102-113
40. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., Kotchen T., Curb J.D., Black H., Rossouw J.E., Aragaki A., Safford M., Stein E., Laowattana S., and Mysiw W.J. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
41. Williamson-Hughes P.S., Flickinger B.D., Messina M.J., and Empie M.W. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 13 (2006) 831-839
42. Yoles I., Yogev Y., Frenkel Y., Nahum R., Hirsch M., and Kaplan B. Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 10 (2003) 522-525